Log in
NASDAQ:MRSN

Mersana Therapeutics Stock Forecast, Price & News

$24.89
-0.62 (-2.43 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$24.77
Now: $24.89
$25.88
50-Day Range
$16.85
MA: $20.51
$25.51
52-Week Range
$3.32
Now: $24.89
$26.64
Volume496,050 shs
Average Volume1.17 million shs
Market Capitalization$1.70 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.44
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Read More
Mersana Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRSN
CUSIPN/A
Phone617-498-0020
Employees83

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.12 million
Book Value$1.64 per share

Profitability

Net Income$-28,210,000.00
Net Margins-4,119.91%

Miscellaneous

Market Cap$1.70 billion
Next Earnings Date2/26/2021 (Estimated)
OptionableNot Optionable
$24.89
-0.62 (-2.43 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

How has Mersana Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRSN stock has increased by 285.3% and is now trading at $24.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Mersana Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mersana Therapeutics
.

What stocks does MarketBeat like better than Mersana Therapeutics?

Wall Street analysts have given Mersana Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mersana Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, February 26th 2021.
View our earnings forecast for Mersana Therapeutics
.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) posted its earnings results on Monday, November, 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.02. The business earned $0.01 million during the quarter, compared to analysts' expectations of $0.43 million. Mersana Therapeutics had a negative net margin of 4,119.91% and a negative return on equity of 54.92%.
View Mersana Therapeutics' earnings history
.

What price target have analysts set for MRSN?

6 equities research analysts have issued twelve-month price objectives for Mersana Therapeutics' stock. Their forecasts range from $20.00 to $32.00. On average, they expect Mersana Therapeutics' stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price.
View analysts' price targets for Mersana Therapeutics
.

Who are some of Mersana Therapeutics' key competitors?

What other stocks do shareholders of Mersana Therapeutics own?

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the following people:
  • Ms. Anna Protopapas, Pres, CEO & Director (Age 56, Pay $833.15k)
  • Mr. Brian C. DeSchuytner, Sr. VP of Fin. & Product Strategy (Age 42, Pay $456.82k)
  • Dr. Dirk Huebner M.D., Chief Medical Officer (Age 57, Pay $987.8k)
  • Mr. Mikhail Papisov Ph.D., Co-Founder
  • Mr. Ashish Mandelia, VP, Controller & Principal Accounting Officer (Age 46)

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.60%), NEA Management Company LLC (8.71%), Consonance Capital Management LP (5.06%), State Street Corp (4.31%), Sarissa Capital Management LP (4.14%) and Alkeon Capital Management LLC (2.26%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Ashish Mandelia, Enterprise Associates 14 New, Eva M Jack, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger.
View institutional ownership trends for Mersana Therapeutics
.

Which institutional investors are selling Mersana Therapeutics stock?

MRSN stock was sold by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, NEA Management Company LLC, AXA S.A., Wells Fargo & Company MN, Connor Clark & Lunn Investment Management Ltd., JPMorgan Chase & Co., Cubist Systematic Strategies LLC, and Thrivent Financial for Lutherans. Company insiders that have sold Mersana Therapeutics company stock in the last year include Ashish Mandelia, Eva M Jack, Scott D Sandell, and Timothy B Lowinger.
View insider buying and selling activity for Mersana Therapeutics
.

Which institutional investors are buying Mersana Therapeutics stock?

MRSN stock was purchased by a variety of institutional investors in the last quarter, including Alkeon Capital Management LLC, State Street Corp, Point72 Asset Management L.P., Sarissa Capital Management LP, Charles Schwab Investment Management Inc., Federated Hermes Inc., Teacher Retirement System of Texas, and BlackRock Inc.. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, Enterprise Associates 14 New, and Lawrence M Alleva.
View insider buying and selling activity for Mersana Therapeutics
.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $24.89.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $1.70 billion and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Mersana Therapeutics employs 83 workers across the globe.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is www.mersana.com.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.